Our Core Research Team
We are twelve independent laboratories working together to find new ways to prevent cancers, better treat cancers and understand how they arise.
DNA Damage Repair Biology
Cellular Aging Biology
Anti-Cancer Clinical Trials
Cancer Exposome Science
Dr. Gwyn Bebb
Short Bio Summary
Dr. Gwyn Bebb is a medical oncologist at the Tom Baker Cancer Centre and an associate professor at the
Arnie Charbonneau Cancer Institute; he also leads the Tom Baker Cancer Centre’s Clinical Research
Unit. He obtained his MD from Oxford University (UK) in 1992 and his PhD from the University of British Columbia
in 1999. In 2004, he opened his own laboratory at the University of Calgary’s Cumming School of Medicine.
In humans, the ATM gene encodes a protein that is critical for preserving genome stability by ensuring a proper cellular response to DNA damage. People born without ATM suffer from the heritable disorder called Ataxia Telangiectasia, characterized (among other symptoms) by increased sensitivity to DNA damage and an elevated risk of cancer. Within the general population, several cancers are now known to show mutations in ATM, including mantle cell lymphoma (MCC, a type of blood cancer) and non-small cell lung cancer (NSCLC).
Our research is focused on targeted therapy of MCC and NSCLC. To facilitate translational research in lung cancer, Dr Bebb led the creation of the Glans-Look lung cancer database, collecting clinical information on almost 6,000 lung cancer patients from the Calgary area, with matching cancer specimens (for most) available for researchers.